Lunai Bioworks Inc (LNAI)
Lunai Bioworks Inc. is a NASDAQ-listed common stock issuer in the healthcare sector focused on biotechnology. The company is a pre-clinical stage biotechnology business with operations in the United States and the Netherlands, and it is organized across three segments: RENB, BioSymetrics, and RENC. Its development pipeline includes genetically modified allogeneic dendritic cell therapeutic vaccines such as RENB-DC11, which is being developed for solid tumors with an emphasis on pancreatic cancer, and RENB-DC20, which is being developed for breast cancer. Lunai Bioworks is also advancing an artificial intelligence platform designed for early cancer detection and recurrence monitoring using a multi-omics approach to identify biomarkers, including in asymptomatic patients. The company is headquartered in Los Angeles, California, and was previously known as Renovaro Inc. before adopting its current name in August 2025.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-LNAI
|
$1.41
|
-50.8% Downside
|
Expensive
|
—
|
—
|
—
|
Weak
|
—
|
—
|
—
|
0.0%
|
September 29, 2026
|
-0.1x
|
-1.3x
|
600.3x
|
11.969 M
|
10.829 M
|
10.5%
|
69.9%
|
-202.9
|
—
|
4.1%
|
